The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The prognosis of patients with recurrent or persistent ovarian clear cell carcinoma: Results from a randomized phase III study (JGOG3017/GCIG).
 
Eiji Kondo
No Relationships to Disclose
 
Tsutomu Tabata
Honoraria - AstraZeneca; Chugai Pharma
 
Nao Suzuki
No Relationships to Disclose
 
Daisuke Aoki
Honoraria - Daiichi Sankyo
 
Osamu Tokuyama
No Relationships to Disclose
 
Kiyoko Kato
No Relationships to Disclose
 
Tetsutaro Hamano
Honoraria - Chugai Pharma
 
Yoshio Kotera
No Relationships to Disclose
 
Keiichi Fujiwara
Honoraria - Bayer; Chugai Pharma; Daiichi Sankyo; Eisai; Janssen Oncology; Kyowa Hakko Kirin; Lilly Japan; Nippon Kayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Zeria Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Eisai; MSD; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Immunogen (Inst); Kaken Pharmaceutical (Inst); Lilly (Inst); MSD (Inst); Oncotherapeutics (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)
 
Eizo Kimura
No Relationships to Disclose
 
Fumitoshi Terauchi
No Relationships to Disclose
 
Toshiyuki Sumi
No Relationships to Disclose
 
Aikou Okamoto
No Relationships to Disclose
 
Nobuo Yaegashi
No Relationships to Disclose
 
Takayuki Enomoto
No Relationships to Disclose
 
Toru Sugiyama
No Relationships to Disclose